Free tool
FAERS Monitor: Xadago
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 207145 or its brand name (Xadago, Safinamide Mesylate). Reports on generic versions are filed under their own applications.
Reports
1,386
Serious
1,086
78% of reports
Hospitalization
597
Death reported
175
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fall177
- dyskinesia162
- hallucination159
- death108
- on and off phenomenon108
- gait disturbance104
- parkinson^s disease98
- drug ineffective95
- tremor89
- fatigue82
- freezing phenomenon78
- somnolence73
- anxiety69
- confusional state69
- nausea69
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2016 | 24 |
| 2017 | 57 |
| 2018 | 112 |
| 2019 | 152 |
| 2020 | 158 |
| 2021 | 144 |
| 2022 | 142 |
| 2023 | 117 |
| 2024 | 136 |
| 2025 | 173 |
| 2026 | 171 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,773 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| freezing phenomenonSignal | 78 | 326.6 | 262.6 | 24,470 |
| on and off phenomenonSignal | 108 | 301.1 | 250.7 | 31,386 |
| dyskinesiaSignal | 162 | 60.7 | 52.5 | 9,438 |
| hallucinationSignal | 159 | 32.1 | 27.7 | 4,764 |
| gait disturbanceSignal | 104 | 8.2 | 6.9 | 661 |
| tremorSignal | 89 | 8.1 | 6.7 | 554 |
| fallSignal | 177 | 8.1 | 7.0 | 1,107 |
| confusional stateSignal | 69 | 6.5 | 5.2 | 317 |
| somnolenceSignal | 73 | 5.5 | 4.4 | 267 |
| anxietySignal | 69 | 3.7 | 2.9 | 134 |
| death | 108 | 1.9 | 1.6 | 47 |
| fatigue | 82 | 1.6 | 1.3 | 18 |
| nausea | 69 | 1.3 | 1.1 | 5 |
| drug ineffective | 95 | 1.1 | 0.9 | 1 |
| parkinson^s disease | 98 | 0.0 | 0.0 | 1,473,435 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.